{"id":14040,"date":"2023-04-03T17:49:56","date_gmt":"2023-04-03T15:49:56","guid":{"rendered":"https:\/\/udic.es\/lassaig-clinic-clarity-ad-ha-demostrat-reduir-la-taxa-de-deterioracio-cognitiva-un-27-en-malalts-dalzheimer\/"},"modified":"2023-04-03T17:49:56","modified_gmt":"2023-04-03T15:49:56","slug":"lassaig-clinic-clarity-ad-ha-demostrat-reduir-la-taxa-de-deterioracio-cognitiva-un-27-en-malalts-dalzheimer","status":"publish","type":"post","link":"https:\/\/udic.es\/ca\/lassaig-clinic-clarity-ad-ha-demostrat-reduir-la-taxa-de-deterioracio-cognitiva-un-27-en-malalts-dalzheimer\/","title":{"rendered":"L&#8217;assaig cl\u00ednic Clarity AD ha demostrat reduir la taxa de deterioraci\u00f3 cognitiva un 27% en malalts d&#8217;Alzheimer"},"content":{"rendered":"<p><strong>L&#8217;Hospital Universitari General de Catalunya ha participat a l&#8217;assaig cl\u00ednic Clarity AD que ha demostrat reduir la taxa de deteriorament cognitiu un 27% en malalts d&#8217;Alzheimer<\/strong><\/p>\n<p>L&#8217;Hospital Universitari General de Catalunya, a trav\u00e9s de la Unitat d\u2019investigaci\u00f3 Cl\u00ednica (UDIC), ha rebut a l&#8217;assaig cl\u00ednic anomenat Clarity AD, de les companyies Eisai i Biogen, que ha aconseguit resultats esperan\u00e7adors en pacients amb Alzheimer en fase inicial. Lecanemab \u00e9s el compost que ha mostrat en assaigs cl\u00ednics la seva efic\u00e0cia i seguretat en reduir el declinar cognitiu produ\u00eft per malaltia d&#8217;Alzheimer en fase inicial.<\/p>\n<p>Els pacients de l&#8217;HUGC que van participar en aquest assaig ho han pogut fer a Fase II, Fase III i a les extensions de l&#8217;estudi obertes fins avui. En total han estat 1.795 pacients els que han pogut ingressar en aquest estudi que mostra que administrar lecanemab redueix la taxa de deteriorament cognitiu un 27%, en comparaci\u00f3 dels que van rebre placebo.<\/p>\n<p>Lecanemab \u00e9s un antiamiloide monoclonal que ataca les plaques de la prote\u00efna amiloide de les neurones dels malalts, una de les principals hip\u00f2tesis de l&#8217;origen de la malaltia. L&#8217;assaig, en qu\u00e8 es va administrar Lecanemab dues vegades per setmana durant 18 mesos, ha aconseguit l&#8217;objectiu principal de l&#8217;estudi, que era demostrar la seva efic\u00e0cia cl\u00ednica en reduir la placa amiloide del cervell, totes les variables secund\u00e0ries han resultat positius i els efectes secundaris estan dins del que s&#8217;espera<\/p>\n<p>Eisai i Biogen sol\u00b7licitaran l&#8217;aprovaci\u00f3 regulat\u00f2ria de lecanemab davant de l&#8217;ag\u00e8ncia regulat\u00f2ria nord-americana i autoritzacions per a la seva comercialitzaci\u00f3 a Europa i Jap\u00f3 per a finals del primer trimestre del 2023. El lecanemab ja \u00e9s revisat pels organismes reguladors dels Estats Units en el marc d&#8217;una via aprovaci\u00f3 especial accelerada.<\/p>\n<p>El Dr. Ernest Balaguer, director de la Unitat d\u2019Investigaci\u00f3 Cl\u00ednica, s&#8217;ha mostrat esperan\u00e7at davant aquests resultats de l&#8217;assaig que demostra l&#8217;efic\u00e0cia de lecanemab en l&#8217;alentiment de la progressi\u00f3 de la malaltia d&#8217;Alzheimer en fase inicial i la seva seguretat. L&#8217;HUGC ha estat el tercer hospital d&#8217;Espanya i el cinqu\u00e8 d&#8217;Europa a la inclusi\u00f3 de pacients en aquest estudi.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>L&#8217;Hospital Universitari General de Catalunya ha participat a l&#8217;assaig cl\u00ednic Clarity AD que ha demostrat reduir la taxa de deteriorament cognitiu un 27% en malalts d&#8217;Alzheimer L&#8217;Hospital Universitari General de Catalunya, a trav\u00e9s de la Unitat d\u2019investigaci\u00f3 Cl\u00ednica (UDIC), ha rebut a l&#8217;assaig cl\u00ednic anomenat Clarity AD, de les companyies Eisai i Biogen, que ha&#8230;<\/p>\n","protected":false},"author":2,"featured_media":9250,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[131,133],"tags":[],"class_list":["post-14040","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-alzeimer-ca-2","category-novetats"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.8 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Reduir la taxa de deterioraci\u00f3 cognitiva un 27% en el alzehimer<\/title>\n<meta name=\"description\" content=\"UDIC ha participat en l&#039;assaig cl\u00ednic que ha demostrat reduir la taxa de deterioraci\u00f3 cognitiva un 27% en malalts d&#039;Alzheimer.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/udic.es\/clarity-ad-que-ha-demostrado-reducir-la-tasa-de-deterioro-cognitivo-un-27-en-enfermos-de-alzheimer\/\" \/>\n<meta property=\"og:locale\" content=\"ca_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Reduir la taxa de deterioraci\u00f3 cognitiva un 27% en el alzehimer\" \/>\n<meta property=\"og:description\" content=\"UDIC ha participat en l&#039;assaig cl\u00ednic que ha demostrat reduir la taxa de deterioraci\u00f3 cognitiva un 27% en malalts d&#039;Alzheimer.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/udic.es\/clarity-ad-que-ha-demostrado-reducir-la-tasa-de-deterioro-cognitivo-un-27-en-enfermos-de-alzheimer\/\" \/>\n<meta property=\"og:site_name\" content=\"UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/UDIC-Unitat-dInvestigaci%c3%b3-Cl%c3%adnica-447149502490430\/\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-03T15:49:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/udic.es\/wp-content\/uploads\/2022\/09\/63342b01d4c2f.r_d.2190-1738.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"948\" \/>\n\t<meta property=\"og:image:height\" content=\"465\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Tito Surribas\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrit per\" \/>\n\t<meta name=\"twitter:data1\" content=\"Tito Surribas\" \/>\n\t<meta name=\"twitter:label2\" content=\"Temps estimat de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minuts\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/udic.es\/clarity-ad-que-ha-demostrado-reducir-la-tasa-de-deterioro-cognitivo-un-27-en-enfermos-de-alzheimer\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/udic.es\/clarity-ad-que-ha-demostrado-reducir-la-tasa-de-deterioro-cognitivo-un-27-en-enfermos-de-alzheimer\/\"},\"author\":{\"name\":\"Tito Surribas\",\"@id\":\"https:\/\/udic.es\/#\/schema\/person\/a8ae8ae960ad58f89663d1d0a2199d1e\"},\"headline\":\"L&#8217;assaig cl\u00ednic Clarity AD ha demostrat reduir la taxa de deterioraci\u00f3 cognitiva un 27% en malalts d&#8217;Alzheimer\",\"datePublished\":\"2023-04-03T15:49:56+00:00\",\"dateModified\":\"2023-04-03T15:49:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/udic.es\/clarity-ad-que-ha-demostrado-reducir-la-tasa-de-deterioro-cognitivo-un-27-en-enfermos-de-alzheimer\/\"},\"wordCount\":375,\"publisher\":{\"@id\":\"https:\/\/udic.es\/#organization\"},\"image\":{\"@id\":\"https:\/\/udic.es\/clarity-ad-que-ha-demostrado-reducir-la-tasa-de-deterioro-cognitivo-un-27-en-enfermos-de-alzheimer\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/udic.es\/wp-content\/uploads\/2017\/07\/logo.png\",\"articleSection\":[\"Alzeimer\",\"Novetats\"],\"inLanguage\":\"ca\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/udic.es\/clarity-ad-que-ha-demostrado-reducir-la-tasa-de-deterioro-cognitivo-un-27-en-enfermos-de-alzheimer\/\",\"url\":\"https:\/\/udic.es\/clarity-ad-que-ha-demostrado-reducir-la-tasa-de-deterioro-cognitivo-un-27-en-enfermos-de-alzheimer\/\",\"name\":\"Reduir la taxa de deterioraci\u00f3 cognitiva un 27% en el alzehimer\",\"isPartOf\":{\"@id\":\"https:\/\/udic.es\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/udic.es\/clarity-ad-que-ha-demostrado-reducir-la-tasa-de-deterioro-cognitivo-un-27-en-enfermos-de-alzheimer\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/udic.es\/clarity-ad-que-ha-demostrado-reducir-la-tasa-de-deterioro-cognitivo-un-27-en-enfermos-de-alzheimer\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/udic.es\/wp-content\/uploads\/2017\/07\/logo.png\",\"datePublished\":\"2023-04-03T15:49:56+00:00\",\"dateModified\":\"2023-04-03T15:49:56+00:00\",\"description\":\"UDIC ha participat en l'assaig cl\u00ednic que ha demostrat reduir la taxa de deterioraci\u00f3 cognitiva un 27% en malalts d'Alzheimer.\",\"breadcrumb\":{\"@id\":\"https:\/\/udic.es\/clarity-ad-que-ha-demostrado-reducir-la-tasa-de-deterioro-cognitivo-un-27-en-enfermos-de-alzheimer\/#breadcrumb\"},\"inLanguage\":\"ca\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/udic.es\/clarity-ad-que-ha-demostrado-reducir-la-tasa-de-deterioro-cognitivo-un-27-en-enfermos-de-alzheimer\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/udic.es\/clarity-ad-que-ha-demostrado-reducir-la-tasa-de-deterioro-cognitivo-un-27-en-enfermos-de-alzheimer\/#primaryimage\",\"url\":\"https:\/\/udic.es\/wp-content\/uploads\/2017\/07\/logo.png\",\"contentUrl\":\"https:\/\/udic.es\/wp-content\/uploads\/2017\/07\/logo.png\",\"width\":815,\"height\":246,\"caption\":\"logo\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/udic.es\/clarity-ad-que-ha-demostrado-reducir-la-tasa-de-deterioro-cognitivo-un-27-en-enfermos-de-alzheimer\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Inici\",\"item\":\"https:\/\/udic.es\/ca\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"L&#8217;assaig cl\u00ednic Clarity AD ha demostrat reduir la taxa de deterioraci\u00f3 cognitiva un 27% en malalts d&#8217;Alzheimer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/udic.es\/#website\",\"url\":\"https:\/\/udic.es\/\",\"name\":\"UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica\",\"description\":\"Unitat D&#039;Investigaci\u00f3 Cl\u00ednica\",\"publisher\":{\"@id\":\"https:\/\/udic.es\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/udic.es\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ca\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/udic.es\/#organization\",\"name\":\"UDIC Unitat D'Investigaci\u00f3 Cl\u00ednica\",\"url\":\"https:\/\/udic.es\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/udic.es\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/udic.es\/wp-content\/uploads\/2017\/08\/logo.png\",\"contentUrl\":\"https:\/\/udic.es\/wp-content\/uploads\/2017\/08\/logo.png\",\"width\":408,\"height\":123,\"caption\":\"UDIC Unitat D'Investigaci\u00f3 Cl\u00ednica\"},\"image\":{\"@id\":\"https:\/\/udic.es\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/UDIC-Unitat-dInvestigaci\u00f3-Cl\u00ednica-447149502490430\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/udic.es\/#\/schema\/person\/a8ae8ae960ad58f89663d1d0a2199d1e\",\"name\":\"Tito Surribas\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/udic.es\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/ae5f603516ade2643999845ead05442c?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/ae5f603516ade2643999845ead05442c?s=96&d=mm&r=g\",\"caption\":\"Tito Surribas\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Reduir la taxa de deterioraci\u00f3 cognitiva un 27% en el alzehimer","description":"UDIC ha participat en l'assaig cl\u00ednic que ha demostrat reduir la taxa de deterioraci\u00f3 cognitiva un 27% en malalts d'Alzheimer.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/udic.es\/clarity-ad-que-ha-demostrado-reducir-la-tasa-de-deterioro-cognitivo-un-27-en-enfermos-de-alzheimer\/","og_locale":"ca_ES","og_type":"article","og_title":"Reduir la taxa de deterioraci\u00f3 cognitiva un 27% en el alzehimer","og_description":"UDIC ha participat en l'assaig cl\u00ednic que ha demostrat reduir la taxa de deterioraci\u00f3 cognitiva un 27% en malalts d'Alzheimer.","og_url":"https:\/\/udic.es\/clarity-ad-que-ha-demostrado-reducir-la-tasa-de-deterioro-cognitivo-un-27-en-enfermos-de-alzheimer\/","og_site_name":"UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica","article_publisher":"https:\/\/www.facebook.com\/UDIC-Unitat-dInvestigaci%c3%b3-Cl%c3%adnica-447149502490430\/","article_published_time":"2023-04-03T15:49:56+00:00","og_image":[{"width":948,"height":465,"url":"https:\/\/udic.es\/wp-content\/uploads\/2022\/09\/63342b01d4c2f.r_d.2190-1738.jpeg","type":"image\/jpeg"}],"author":"Tito Surribas","twitter_card":"summary_large_image","twitter_misc":{"Escrit per":"Tito Surribas","Temps estimat de lectura":"2 minuts"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/udic.es\/clarity-ad-que-ha-demostrado-reducir-la-tasa-de-deterioro-cognitivo-un-27-en-enfermos-de-alzheimer\/#article","isPartOf":{"@id":"https:\/\/udic.es\/clarity-ad-que-ha-demostrado-reducir-la-tasa-de-deterioro-cognitivo-un-27-en-enfermos-de-alzheimer\/"},"author":{"name":"Tito Surribas","@id":"https:\/\/udic.es\/#\/schema\/person\/a8ae8ae960ad58f89663d1d0a2199d1e"},"headline":"L&#8217;assaig cl\u00ednic Clarity AD ha demostrat reduir la taxa de deterioraci\u00f3 cognitiva un 27% en malalts d&#8217;Alzheimer","datePublished":"2023-04-03T15:49:56+00:00","dateModified":"2023-04-03T15:49:56+00:00","mainEntityOfPage":{"@id":"https:\/\/udic.es\/clarity-ad-que-ha-demostrado-reducir-la-tasa-de-deterioro-cognitivo-un-27-en-enfermos-de-alzheimer\/"},"wordCount":375,"publisher":{"@id":"https:\/\/udic.es\/#organization"},"image":{"@id":"https:\/\/udic.es\/clarity-ad-que-ha-demostrado-reducir-la-tasa-de-deterioro-cognitivo-un-27-en-enfermos-de-alzheimer\/#primaryimage"},"thumbnailUrl":"https:\/\/udic.es\/wp-content\/uploads\/2017\/07\/logo.png","articleSection":["Alzeimer","Novetats"],"inLanguage":"ca"},{"@type":"WebPage","@id":"https:\/\/udic.es\/clarity-ad-que-ha-demostrado-reducir-la-tasa-de-deterioro-cognitivo-un-27-en-enfermos-de-alzheimer\/","url":"https:\/\/udic.es\/clarity-ad-que-ha-demostrado-reducir-la-tasa-de-deterioro-cognitivo-un-27-en-enfermos-de-alzheimer\/","name":"Reduir la taxa de deterioraci\u00f3 cognitiva un 27% en el alzehimer","isPartOf":{"@id":"https:\/\/udic.es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/udic.es\/clarity-ad-que-ha-demostrado-reducir-la-tasa-de-deterioro-cognitivo-un-27-en-enfermos-de-alzheimer\/#primaryimage"},"image":{"@id":"https:\/\/udic.es\/clarity-ad-que-ha-demostrado-reducir-la-tasa-de-deterioro-cognitivo-un-27-en-enfermos-de-alzheimer\/#primaryimage"},"thumbnailUrl":"https:\/\/udic.es\/wp-content\/uploads\/2017\/07\/logo.png","datePublished":"2023-04-03T15:49:56+00:00","dateModified":"2023-04-03T15:49:56+00:00","description":"UDIC ha participat en l'assaig cl\u00ednic que ha demostrat reduir la taxa de deterioraci\u00f3 cognitiva un 27% en malalts d'Alzheimer.","breadcrumb":{"@id":"https:\/\/udic.es\/clarity-ad-que-ha-demostrado-reducir-la-tasa-de-deterioro-cognitivo-un-27-en-enfermos-de-alzheimer\/#breadcrumb"},"inLanguage":"ca","potentialAction":[{"@type":"ReadAction","target":["https:\/\/udic.es\/clarity-ad-que-ha-demostrado-reducir-la-tasa-de-deterioro-cognitivo-un-27-en-enfermos-de-alzheimer\/"]}]},{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/udic.es\/clarity-ad-que-ha-demostrado-reducir-la-tasa-de-deterioro-cognitivo-un-27-en-enfermos-de-alzheimer\/#primaryimage","url":"https:\/\/udic.es\/wp-content\/uploads\/2017\/07\/logo.png","contentUrl":"https:\/\/udic.es\/wp-content\/uploads\/2017\/07\/logo.png","width":815,"height":246,"caption":"logo"},{"@type":"BreadcrumbList","@id":"https:\/\/udic.es\/clarity-ad-que-ha-demostrado-reducir-la-tasa-de-deterioro-cognitivo-un-27-en-enfermos-de-alzheimer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Inici","item":"https:\/\/udic.es\/ca\/"},{"@type":"ListItem","position":2,"name":"L&#8217;assaig cl\u00ednic Clarity AD ha demostrat reduir la taxa de deterioraci\u00f3 cognitiva un 27% en malalts d&#8217;Alzheimer"}]},{"@type":"WebSite","@id":"https:\/\/udic.es\/#website","url":"https:\/\/udic.es\/","name":"UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica","description":"Unitat D&#039;Investigaci\u00f3 Cl\u00ednica","publisher":{"@id":"https:\/\/udic.es\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/udic.es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ca"},{"@type":"Organization","@id":"https:\/\/udic.es\/#organization","name":"UDIC Unitat D'Investigaci\u00f3 Cl\u00ednica","url":"https:\/\/udic.es\/","logo":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/udic.es\/#\/schema\/logo\/image\/","url":"https:\/\/udic.es\/wp-content\/uploads\/2017\/08\/logo.png","contentUrl":"https:\/\/udic.es\/wp-content\/uploads\/2017\/08\/logo.png","width":408,"height":123,"caption":"UDIC Unitat D'Investigaci\u00f3 Cl\u00ednica"},"image":{"@id":"https:\/\/udic.es\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/UDIC-Unitat-dInvestigaci\u00f3-Cl\u00ednica-447149502490430\/"]},{"@type":"Person","@id":"https:\/\/udic.es\/#\/schema\/person\/a8ae8ae960ad58f89663d1d0a2199d1e","name":"Tito Surribas","image":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/udic.es\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/ae5f603516ade2643999845ead05442c?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ae5f603516ade2643999845ead05442c?s=96&d=mm&r=g","caption":"Tito Surribas"}}]}},"_links":{"self":[{"href":"https:\/\/udic.es\/ca\/wp-json\/wp\/v2\/posts\/14040"}],"collection":[{"href":"https:\/\/udic.es\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/udic.es\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/udic.es\/ca\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/udic.es\/ca\/wp-json\/wp\/v2\/comments?post=14040"}],"version-history":[{"count":0,"href":"https:\/\/udic.es\/ca\/wp-json\/wp\/v2\/posts\/14040\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/udic.es\/ca\/wp-json\/wp\/v2\/media\/9250"}],"wp:attachment":[{"href":"https:\/\/udic.es\/ca\/wp-json\/wp\/v2\/media?parent=14040"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/udic.es\/ca\/wp-json\/wp\/v2\/categories?post=14040"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/udic.es\/ca\/wp-json\/wp\/v2\/tags?post=14040"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}